Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- Instituto Mexicano del Seguro Social
- Target Recruit Count
- 320
- Registration Number
- NCT01234129
- Locations
- 🇲🇽
Tertiary reference oncology center, Mexico, Distrito Federal, Mexico
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
- Conditions
- Interventions
- First Posted Date
- 2010-10-26
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 63
- Registration Number
- NCT01228318
- Locations
- 🇺🇸
Grady Infectious Diseases Clinic (Ponce Center), Atlanta, Georgia, United States
Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis
- Conditions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Turku University Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT01218035
- Locations
- 🇫🇮
Turku University Hospital, Turku, Finland
1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01197300
- Locations
- 🇬🇧
Novartis Investigative Site, West Midlands, Birmingham, United Kingdom
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2018-09-12
- Target Recruit Count
- 63
- Registration Number
- NCT01194440
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Zoledronic Acid in MS-patients With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- Novartis
- Target Recruit Count
- 29
- Registration Number
- NCT01166178
- Locations
- 🇩🇪
Novartis Investigative Site, Siegen, Germany
🇩🇪Novartis investigative site, Stade, Germany
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 33
- Registration Number
- NCT01153425
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT01129336
- Locations
- 🇺🇸
Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States
🇺🇸Wilshire Oncology Medical Group, La Verne, California, United States
🇺🇸Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Borstkanker Onderzoek Groep
- Target Recruit Count
- 250
- Registration Number
- NCT01099436
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
- Conditions
- Interventions
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 103
- Registration Number
- NCT01087008
- Locations
- 🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸Hospital Universitario de Salamanca, Salamanca, Spain
🇪🇸Hospital Universitari Germans Trias I Pujol, Badalona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.